Genomes and Genes

Species

Masahiro Mori

Summary

Affiliation: Chiba University
Country: Japan

Publications

  1. Masuda H, Mori M, Uzawa A, Uchida T, Ohtani R, Kobayashi S, et al. Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:64-68 pubmed publisher
    ..No correlations were observed between serum IL-6 levels and either score. MFIS was validated in patients with NMOSD. Serum IL-6 levels may not be involved in the pathogenesis of fatigue and pain in patients with NMOSD. ..
  2. Sugimoto K, Hiwasa T, Shibuya K, Hirano S, Beppu M, Isose S, et al. Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. J Neuroimmunol. 2018;325:54-60 pubmed publisher
    ..01). Serum anti-PSMA7 antibody might be a disease-promoting factor in early-stage ALS and might be a biomarker of ALS. Anti-PSMA7 autoantibody might contribute to the pathogenesis of ALS, possibly via its role in the UPP. ..
  3. Muto M, Mori M, Hiwasa T, Takiguchi M, Iwadate Y, Uzawa A, et al. Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. J Neuroimmunol. 2015;284:30-6 pubmed publisher
    ..Moreover, we found negative-correlations between serum anti-talin1 antibody and IgG index in MS (P = 0.03). Anti-talin1 antibody exists in MS patients' sera, which may have some protective factor. ..
  4. Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, et al. Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. J Neurol. 2018;265:1145-1150 pubmed publisher
    ..Fingolimod treatment is likely to increase serum JCVAb index, possibly leading to the development of PML. Therefore, it is advised that JCVAb index should be serially monitored during fingolimod treatment to decrease PML risk. ..
  5. Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Ohtani R, et al. Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. J Neurol Sci. 2016;367:375-9 pubmed publisher
    ..030 and 0.059, respectively). In MS, relapsed ON also reached nadir earlier (P=0.042); however, there was no difference in recovery. Recovery from ON was poorer in NMOsd than in MS and was negatively affected by previous ON attacks. ..
  6. Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R, Kuwabara S. Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. J Neuroimmunol. 2017;305:102-107 pubmed publisher
    ..sCD40L could be involved in BBB disruption in MS, whereas it may contribute to CNS inflammation in NMOSD. ..
  7. Masuda H, Mori M, Umehara K, Furihata T, Uchida T, Uzawa A, et al. Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2018;: pubmed publisher
    ..BBB permeability was increased by administering sCD40L in a HBMEC-based BBB model. Thus, sCD40L induces more severe inflammation in the central nervous system by disrupting the BBB. ..
  8. request reprint
    Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007;68:1144-6 pubmed
    ..In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery...
  9. Muto M, Mori M, Liu J, Uzawa A, Uchida T, Masuda H, et al. Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. J Neuroimmunol. 2017;305:131-134 pubmed publisher
    ..sTalin-1 may be a biomarker for the acute phase of MS and may be used for the short-term prognosis of MS. ..